-
Trial Will Test IRL790 in Parkinson’s Levodopa-induced Dyskinesia in 2020
IRLAB Therapeutics will test IRL790 in a Phase 2b/3 study in 2020 as an oral treatment candidate for levodopa-induced dyskinesia in Parkinson’s. Read more here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.